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Age Factors Potentiating Drug Toxicity in
the Reproductive Axis
by Richard F. Walker*
Traditionally, drug toxicity in the reproductive system has been a concern only as it affects fertility
and fecundity in young individuals. The purpose of this report is to address the potential problem of
synergy between drug actions and abnormal secretion of reproductive hormones that together produce
disease in older individuals. Thus, reproductive toxicity has different, but no less serious implications in
aging individuals. During aging, the coordinated function of elements within the reproductive neuroen-
docrine axisdegrades. Thischange promotesatypical secretion ofhormonesproducingabnormalresponses
in target organs and thus creates a condition with pathogenic potential. Certain drugs may contribute to
reproductive toxicity in aging individuals either by accelerating the process of dysregulation and/or by
synergizing with hormones to stimulate pathologic changes in target tissues. The geriatric population of
the world is increasing, and since it consumes a proportionately larger percentage ofdrugs than younger
groups, this novel form of reproductive toxicity may represent a problem in drug safety that warrants
serious consideration.
Introduction
Postmenopausal women sometimes participate in
phase I clinicaltrials ofdrug development because they
lack menstrual cycles, a fact that seemingly precludes
the need for concern about potential reproductive tox-
icity. The disregard for reproductive consequences of
drug treatment in these subjects seems perfectly ap-
propriate, sinceintuitively, the issue should berelevant
only to those women with ovarian cycles who are ca-
pableofbecomingpregnantandbearingoffspring. How-
ever, more in-depth consideration reveals that this at-
titude focuses concern for reproductive toxicity only
indirectly toward the individual being medicated. In
effect, the prime focus ofreproductive toxicity studies
is, in general, the future generation, with minimal re-
gard for the present one except to ensure that the
drug(s) in question does not alter its capacity to repro-
duce. That the goal of reproductive toxicity determi-
nationsisultimatelytoavoiddrug-inducedreproductive
dysfunction is obvious, and to criticize this goal is not
the intent ofthe present argument.
Instead, it is to suggest that an equally valid goal of
reproductive toxicity studies is to define interactions of
drugs with components of the hypothalamo-pituitary-
ovarian axis that may be detrimental to the health of
thetreated individual. Forexample, sincecyclicovarian
function is absent in postmenopausal women, it would
seem that the question of whether or not a drug per-
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turbs ovarian cycles in these individuals is moot. How-
ever, despite the fact that ovarian activity in aged
women is not cyclic, elements ofthe reproductive axis
continue to function-albeit abnormally-creating a
hormonalmilieuthatcanbepathogenic. Thus, abnormal
reproductive function in peri- and postmenopausal
women may increase their risk for developing certain
types of disease. Compounding this problem is the po-
tential for toxic interactions ofdrugs with reproductive
hormones whose secretion has become abnormal. Syn-
ergistic effects of these factors may have significant
ramifications upon the patient's health. An example of
this toxic potential that has received notoriety overthe
past few years is the increased incidence ofuterine and
breast cancer resulting from treatment of postmeno-
pausal women with estrogenic compounds (1-4). At-
tempts to use these compounds to reverse or retard
degenerative diseases derive from the fact that the dis-
eases result-at least in part-from declining ovarian
function. To a certain degree, replacement therapy has
been successful. However, treatmenthasalsoincreased
the incidence of certain neoplastic diseases, notably
those ofthe reproductive organs.
As discussed below, these findings demonstrate that
reproductive aging does not result from simple loss of
estrogen production. Instead, the ovary degenerates,
and normal patterns ofestrogen production and secre-
tionfallas aconsequence ofagechangesthatundermine
integrated activity within the entire reproductive neu-
roendocrine axis. The impact ofthese changes upon the
organismismuchmoresignificantthan simpledepletion
ofovarian primordial follicles. Loss ofintegrated activ-
ity leads to internal chaos in a system that requiresR. F. WALKER
strictly ordered events for proper function and main-
tenance ofhealth. In this fragile state, the menopausal
female is more apt to suffer toxic effects from drugs
that produce only modest responses in younger individ-
uals. Thus, the purpose of this paper is to analyze
changes that occur in reproductive function during se-
nescence, focussing upon the possible ramifications of
such change in terms of enhanced drug toxicity and
resultant pathology in the aging female.
Changes in Reproductive Function
during Aging
The major hypothesis ofthis study is that the poten-
tial for drug toxicity is amplified in the dysregulated
reproductive neuroendocrine axis of aging females.
Thus, abriefdescription ofhormonalchangesthatoccur
in females during senescence is an appropriate prelude
to analysis of putative mechanisms for such toxicity.
Figure 1 shows typical levels of reproductive hor-
monesinreproductive and postreproductive women (5).
Since gonadotropin levels are high and steroids are low
in the older group, the data suggest that during aging
the ability of the ovary to produce estrogen declines.
This in turn leads to compensatory output of pituitary
gonadotropins. Support for this view derives from the
histology of ovaries from postmenopausal women that
clearly lack primordial follicles (6). Thus, it has been
suggested that simple depletion ofthese germinal cen-
ters accounts forreproductive senescence in women (7).
However, morecarefulscrutinyofclinicalreports show-
inghormonal profiles ofwomen in transition from cyclic
to acyclic states, as well as analysis ofdata from animal
studies, suggests that age changes in female reproduc-
tive function occur initially at extraovarian sites, then
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spread throughout the axis to finally impact upon the
ovary. As discussed below, the subtle and progressive
alterations inreproductive homeostasishavepotentially
greater health implications than simple decline in es-
trogen production by the ovary.
As female rodents (8) and primates (9) approach mid-
dle age and beyond, their reproductive cycles increase
in length as the frequency of ovulation decreases. This
effect is due in part to alterations in the pattern(s) of
gonadotropin secretion. In rats, progressive delay in
onset and attenuation of the preovulatory surge of lu-
teinizing hormone (LH surge) continues until the tem-
poral and quantitative perturbations cause ovulatory
irregularity. These changes are summarized in Figure
2. Presumably, altered gonadotropin release results ul-
timately from CNS perturbations affecting at least the
metabolism and secretion of monoamines (10-12). In
general terms, these changes are reciprocal between
catecholamines and serotonin (13), ultimately shifting
the nature of monoamine signals to the pituitary from
catecholamines to those predominated by serotonin.
This imbalance of monoamine signals leads not only to
a decremental gonadotropin secretion, but also to hy-
persecretion ofprolactin (14), a condition which has sig-
nificant health implications and is directly related to the
problem of drug toxicity and reproductive senescence.
Paradoxically, a concomitant ofthese changes at the
ovarian level is different from what is expected when
examining end-stage ovaries from postmenopausal fe-
males. During cycle extension at the perimenopausal or
periestropausal interval, quite often estrogen release
from the ovary is enhanced rather than retarded. As
seen in Figure 3, the enhancement is not reflected by
increased peaklevels ofthe steroid in serum, butrather
by extended release at relatively high levels. This al-
tered secretion of estrogen may result from the fact
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FIGURE 1. Circulating levels ofpituitary and steroid hormones in postmenopausal women as compared with premenopausal women studied
during the first week (days 2 to 4) ofthe menstrual cycle. From Yen (5).
-4
186AGING AND REPRODUCTIVE TOXICOLOGY
b C
'500 'Sao a0 0
TIME
FIGURE 2. Serum LH (mean ± SEM) in middle-aged females on the afternoon and evening of vaginal proestrus. Sampling was initiated (a)
at 1500 hr, (b) 1800 hr and (c) 2100 hr. Animals were grouped according to the time their LH peak was observed. In (a) the maximum LH
value for the rats in which the LH peak was observed at 2100 hr (A) was significantly lower than the maximum LH values observed in
those rats which peaked at 1800 hr (0) and 1930 hr (e) (Student's t test, p < 0.05). The maximum LH values ofthose rats in which the LH
peak was observed at 1800 hr and 1930 hr were not significantly different than the peak LH values observed in young rats. The number
of animals in each group is indicated in parentheses. The SEM is indicated only for those groups composed of four or more rats. From
Cooper et al. (11).
April
FIGURE 3. Daily concentrations of serum LH, FSH, E2,.and P dur-
ing four cycles in one 49-year-old subject during the menopausal
transition. Hormone levels are arrayed by calendar date and the
hatched area indicates menstruation. From Sherman et al. (9).
that at the perimenopause, graffian follicles tend not to
ovulate, but instead they accumulate in the ovary and
sometimes become cystic (7,15,16).
Similar changes that occur in the rodent ovary as the
animal enters constant estrus (8) are apparently re-
sponsible for changes in secretory patterns and serum
levels of estradiol. Estrogen depresses LH secretion
and stimulates prolactin release from the pituitary (17).
Thus, these ovarian changes resulting from the initial
perturbation exacerbate and accelerate dysregulation
within the reproductive axis. A positive feedback re-
lationship develops which ultimately becomes cata-
strophic to cyclic reproductive function. This cata-
strophic cascade phenomenon can be demonstrated
experimentally when gonadotropins are depleted with
antibodies. The depletion produces anticipated drops in
gonadal steroidogenic capacity and is also associated
with enhanced prolactin secretion. However, when the
primary perturbation (gonadotropin depletion) is main-
tained, irreversible secondarydamageultimatelyoccurs
to germinal elements, and the functional capacity ofthe
gonad is irrevocably lost (18,19). Thus, experimental
suppression of gonadotropin is sufficient to cause per-
manent damage to the gonad. Examination ofthe prod-
uct ofthis experimental manipulation reveals an animal
with atrophic gonads and a hypergonadotrophic pitui-
tary. The real significance ofthe modelwould be missed
if the transition state, when gonadotropins were low
and prolactin was high, were ignored. During the tran-
sition, conditions occur which clearly allow toxicity of
certain drugs to be expressed. In the natural condition
(during aging), gonadotropins are not blocked by anti-
bodies. However, erosion of neuroendocrine mecha-
nisms that time critical events within the reproductive
axis, such aspreovulatoryrelease ofgonadotropin, have
the sameeffect. Ratherthaneliminatinggonadotropins,
thetemporalpresentationofgonadotropinstothe ovary
isimproper, producinginappropriate responses from an
ovary that is physiologically unprepared for its ovula-
tory stimulus.
Thus, the seemingly innocuous temporal changes in
gonadotropin secretion during aging have serious func-
tionalimplications because they undermine the time re-
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FIGURE 4. Mean LH, FSH, progesterone, estradiol, and 17-OH pro-
gesterone levels in blood specimens collected daily throughout
presumptive ovulatory menstrual cycles from normal women.
Cycle days were synchronized around day of LH peak = day 0.
From Thorneycroft et al. (39).
lationships that are elemental to functional integration
of the total axis. In addition, poorly regulated release
of reproductive hormones from the pituitary and inap-
propriately stimulated ovaries, in turn, cause target
tissues to receive abnormal stimulation. This situation
has the potential to produce aberrant responses in the
target cells, increasing in some cases, their risk of de-
veloping disease.
Estrogen and Prolactin
Although estrogen and prolactin perform functions
that are essential for reproductive cycles in females,
they also are potent substances having the potential to
cause degenerative change and disease. As seen in Fig-
ure 4, the rise and fall ofestrogen and prolactin in con-
junction with other endocrine factors are temporally
correlated with events needed for ovulation. Of signif-
icance is the fact that the negative effects of estrogen
and prolactin are expressed when the limits ofexposure
defined by the temporal constraints of normal repro-
ductive cycles are violated. Thus, in the aging female,
cycles are irregular, and hormone secretions are not
coordinated, providing an environment in which their
pathogenic potential is realized. During cycle dysreg-
ulation in the middle-age transition, estrogen release is
often prolonged (Fig. 3).
The significance ofthis phenomenon is demonstrated
in animal studies that test the effect ofestrogen on cell
viabilityinhypothalamic locithatregulate reproductive
cycles (20). The studies show that prolonged adminis-
tration of estrogen causes cycle instability and ulti-
mately cycle failure (20,21). These effects are presum-
ably mediated by an impact ofthe steroid on the brain,
where altered metabolism ofhypothalamic monoamines
and degeneration ofneurons in the arcuate nucleus fol-
low administration of estrogen (21,22). Pharmacodyn-
amic changes include alterations in the metabolism of
serotonin (22), whose intermittent metabolism and se-
cretionhasbeenlinkedtophasicsecretionofLH(23,24).
Estrogen abolishes the rhythmic metabolism of brain
serotonin, thus perturbing the signal needed for phasic
release of LH. Furthermore, estrogen also stimulates
prolactin release fromthe pituitary. Since as previously
described, prolactin hypersecretion causes degenera-
tion ofgerminal centers within the gonads (25) and also
promotes the growth ofmammary and pituitarytumors
(26,27), its release increases the incidence ofpathology.
The relevance of these facts to discussion of the re-
productive system and drug toxicity derives from the
fact that the aged are often treated with drugs that
have the potential to accelerate the changes in estrogen
and/or prolactin secretion that normally occur during
aging. These effects increase the chances for realizing
the pathogenic potential of the drugs. For example,
aging women suffer symptoms of the menopause that
can be related to estrogen deficits. Based upon the un-
derstanding of reduced steroidogenic capacity of the
aging ovary shown in Figure 1, estrogenic compounds
have been administered in an attempt to relieve these
symptoms. However, as the results of such "replace-
ment therapy," these women increase their risk of de-
veloping diseases of the reproductive tract and mam-
mary glands. Thus, while reasonable in concept,
replacing a deficient hormone does not only accomplish
the desired effect, it increases the risk of developing
disease by exacerbating the process of senescence in
the reproductive system itself.
In addition to these estrogenic effects on the repro-
ductive tract, the incidence of neoplastic disease af-
fecting the mammary gland and pituitary also increase
with aging. Certain drugs synergizing with these
changes can thus show increased reproductive toxicity.
These can occur in estrogenic compounds as well as in
certain neuroleptic compounds that alter monoamine
metabolism.
Serotoninergic Drugs and Pituitary
Neoplasms
Pituitary adenomas occur more frequently in aged
than in young animals, with females having the higher
incidence (27-29). Although the reasons for the sex dif-
ference not established conclusively, itprobably results
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Table 1. Anterior pituitary 5-HT content in rats of different age
and reproductive status.'
Anterior Anterior pituitary 5-HT,
pituitary pg ± SEM
weight
Group N (mg ± SEM) Content Concentration
Young
Estrus 9 14.3 ± 0.77 1973 ± 410 137.6 ± 28
Diestrus 6 13.5 ± 0.89 1710 ± 349 126.5 ± 25
Middle-aged
Diestrus 6 14.1 ± 0.95 2323 ± 386 164.8 ± 27
Constant 7 17.8 ± 1.14* 3394 ± 840t 190.6 ± 47
Estrus
*Pituitaries significantly (p < 0.05) heavier than all other groups.
tPituitaries serotonin content significantly (p < 0.05) greater than
two young groups.
aData from Walker and Cooper (38).
from abnormal exposure offemales to estrogen (30,31).
In addition to these pituitary effects, estrogen alters
CNS monoamine metabolism as described above (32).
This effect is expressed ultimately upon the pituitary
in which dopamine inhibition of lactotrope function is
reduced, while their stimulation by serotonin is in-
creased.
Collectively, these findings suggest that under con-
ditions ofmonoamine imbalance duringaging, abnormal
secretion of ovarian estrogen promotes abnormal pro-
lactin secretion leading ultimately to development of
pituitary and mammary adenomas. Under such precar-
ious conditions, it would appear that drugs with the
potential to further destabilize the reproductive axis
should be more toxic in aged than in young individuals.
In an attempt to evaluate this hypothesis, a study
wasperformed todetermineifserotoninergicdrugs syn-
ergize with hormonal environments ofaged rats to pro-
mote tumor development in the pituitary. In the first
part ofthe study, pituitary serotonin content was com-
pared in young and middle aged female rats. The data
presented inTable 1 showthat meanpituitary serotonin
content and concentration were highest in aged rats
whose reproductive functions were acyclic. Pituitaries
from aged rats that were cycling had serotonin levels
that were comparable to young animals. These findings
suggest that reproductive status and not age per se
correlates with changes in the pituitary that are poten-
tially pathogenic.
During the next phase ofthe study, young rats were
given estrogen by subcutaneous implants ofsilastic cap-
sules that released the steroid abnormally, i.e., in a
constant, nonphysiologic pattern. As seen in Table 2,
pituitary size and serotonin content were elevated (p <
0.01 and p < 0.05) in these animals in a fashion resem-
bling that seen in aged rats.
Finally, estrogen-treated ratsreceived serotonin neu-
roleptics to determine if toxicity of the drugs is en-
hanced by endocrine conditions simulating those that
occur during aging. As seen in Table 3, the tumorigenic
effect ofestrogen on the pituitary was enhanced in rats
receiving concomitant treatment with serotonin recep-
Table 2. Effects of estrogen on pituitary weight and 5-HT
content.'
Pituitary 5-HT, pg ± SEM
Group N Weight, g Content Concentration
Young females
OVX 5 13.6 ± 0.54 1983 ±359 145.8 ± 26
OVX + 6 36.2 ± 1.55t 3120 415* 85.1 ± 11*
estrogen
(5 mmole)
OVX + 6 29.2 ± 1.06t 2780 510 95.2 ± 17
estrogen
(2 mmole)
Middle-aged
females
Constant 7 17.8 ± 1.14 3394 +840 190.6 + 47
estrus
OVX 6 15.2 ± 0.95 2619 + 610 172.3 ± 40
(previ-
ously CE)
Young males
Castrated 6 14.4 ± 0.61 1629 ±439 113.1 30
Castrated 6 27.3 ± 1.Olt 2754 ± 480* 100.6 ± 18
+
estrogen
(5 mm)
*Significantly different (p < 0.05) than gonadectomized control.
tp < 0.01.
aData from Walker and Cooper (38).
tor agonists. Rats receiving combined treatment with
estrogen and zimelidine had heavier pituitaries (p <
0.05) containing more macroadenomas than did rats
treated with estrogen alone. None ofthe serotonin neu-
roleptics altered pituitary weight or the frequency of
adenomas when they were given without estrogen (Ta-
ble 3).
In contrast to these effects of serotonin receptor ag-
onists, drugs that antagonize age changes have bene-
ficial effects on health. Forexample, catecholamine pre-
cursors and receptor agonists reduce the incidence of
neoplastic and nonneoplastic disease during aging (33),
restore menstrual bleeding in postreproductive females
(34) and stimulate reproductive cycles in aged animals
(33,35).
Table 3. Effects of 5-HT receptor agonists and estrogen on
pituitary hypertrophy and tumorigenesis in 4-month-old,
ovariectomized rats.8
Number of rats
Pituitary weight, with
Treatment N (mg-% + SEM macroadenomas
OVXb 4 12.0 ± 0.82t 0
Estrogen 5 36.6 ± 3.95 0
Estrogen + PCPA 6 32.2 ± 2.87 0
Estrogen + 5-HTP 7 38.4 ± 3.54 0
Estrogen + zimelidine 7 78.6 ± 18.00* 3
Estrogen + quipazine 5 53.2 ± 13.60 1
Zimelidineb 4 14.2 ± 0.71* 0
Quipazineb 4 12.6 ± 0.69t 0
'Data from Walker and Cooper (38).
bAnimals had empty Silastic capsules implanted subcutaneously.
tThe pituitary weight of these three groups was significantly
smaller (p < 0.05) than those groups receiving estrogen implants.
*Significantly larger (p < 0.05) thanall other groups exceptestro-
gen + quipazine.
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Discussion and Conclusion
The major goal of this study was to highlight pecu-
liarities of reproductive function in aging females that
provide an environment in which potential toxicity of
certain drugs can be expressed. In this regard, it is not
the obvious deficit in ovarian activity seen in late post-
menopausal women that is ofconcern. Instead, the ero-
sion ofintegrated function within the reproductive neu-
roendocrine axisthat begins and progresses throughout
middle-age creates an endocrine milieu with pathogenic
potential that is amplified by certain drugs. Although
this progressive dysregulation makes most, if not all,
organs ofthebodymorevulnerable todisease, thepres-
ent study focused upon the reproductive axis per se,
considering the effects of abnormal estrogen and pro-
lactin secretion in conjunction with monoamine neuro-
leptics upon development of pituitary adenomas. Spe-
cifically, clinical and experimental evidence was
providedtoshowthatovariansecretion ofestrogendoes
not simply decline with advancing age. Instead, irreg-
ular reproductive cycles beginning in middle age are
accompanied by abnormal secretion of the steroid.
Thereisnotaprecisepatternofestrogenreleaseduring
this period of instability, but, in general, secretion of
the hormone is prolonged as the pattern of phasic or
intermittent release seen in youth is lost. The cause(s)
of perturbations in ovarian function are unknown, but
in rodent models they seem to result from central neu-
rotransmitter changes that alter the pattern ofgonad-
otropin release from the pituitary.
In any event, it is proposed that the protracted re-
lease ofestrogen resulting from such central monoami-
nergic perturbations exacerbates the primary lesion by
altering the metabolism of serotonin and catechol-
amines. This effect also initiates catastrophic feedback
processes involving prolactin that lead to irreversible
degeneration of the gonad. Under these conditions,
drugs with estrogenic or serotoninergic action are ex-
pected to further promote dysregulation and thus tox-
icity, whichwouldnotoccurintheyouthful, functionally
integrated reproductive axis. Specifically, it was shown
that the serotonin receptor agonists quipazine and zi-
melidine enhanced the hypertrophic effect of estrogen
uponthepituitaryandincreasedtheincidenceoftumors
in that tissue.
Differentialtoxicity ofthese drugs is dependentupon
endocrine background, as demonstrated bythefactthat
neither ofthe neuroleptics were tumorigenic in the ab-
sence ofestrogen. Thus, drug-induced pituitary tumors
in the rodent model seem to be secondary to changes
in neuroendocrine events that make the animal more
vulnerable to negative aspects of the drug action. The
findings ofthis study that consider serotoninergic neu-
roleptics and pituitary adenomas may have clinical rel-
evance, since drugs such asbromocryptine that are cur-
rently used to regress lactotroph adenomas in human
(36) possess weak antiserotoninergic activity (37) in ad-
dition to their dopamine agonistic effects. Perhaps, in
the future, the use of drugs that are strong serotonin
receptor antagonists in addition to being dopamine ag-
onists will prove beneficial to the management of pa-
tients with certain types of pituitary tumors.
In conclusion, the purpose ofthis report is to suggest
that the scope of studies in reproductive toxicology
should be expanded to consider the effects of drugs in
individuals beyond their reproductive years, as well as
in those that are reproductively competent. These two
focuses aredifferentinthattraditionalconcernhasbeen
1800for maintaining fertility and preventing congenital
defects. However, drugtoxicityrelated toreproductive
function in aging individuals is another equally valid
issue, and with the current expansion of the geriatric
population, it is one that undoubtedly deserves atten-
tion.
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